Engineering Pathways, Delivery Strategies, and Clinical Translation of Ex Vivo and In Vivo CAR-T Cell Therapy
Engineering Pathways, Delivery Strategies, and Clinical Translation of Ex Vivo and In Vivo CAR-T Cell Therapy
CAR-T cell therapy has achieved substantial efficacy in multiple hematological malignancies, but ex vivo cell manufacturing requires a long production cycle and involves complex procedures. The development of targeted in vivo delivery technologies has provided a new engineering pathway for generating CAR-T cells directly within patients.
Keywords: CAR-T cell; ex vivo CAR-T; in vivo CAR-T; chimeric antigen receptor; T-cell engineering; lentiviral vector; lipid nanoparticle; targeted delivery; cell therapy; clinical translation
1 Mechanism of Action and Technological Evolution of CAR-T Cell Therapy
1.1 Structural Composition of Chimeric Antigen Receptors
A chimeric antigen receptor (CAR) generally consists of an antigen-binding domain, hinge region, transmembrane domain, and intracellular signaling domain. The antigen-binding domain recognizes antigens on the surface of tumor cells, the hinge region regulates the spatial distance between the receptor and target antigen, and the transmembrane domain influences receptor stability and membrane localization. The intracellular CD3ζ domain triggers T-cell activation, whereas costimulatory domains such as CD28 or 4-1BB regulate cell proliferation, metabolic status, and functional persistence.
1.2 Targeted Cytotoxic Mechanism of CAR-T Cells
Binding of CAR to its target antigen promotes immune synapse formation, enabling T cells to release perforin and granzymes and produce cytokines such as IFN-γ, TNF, and IL-2. CAR-mediated recognition does not depend on major histocompatibility complex presentation and can therefore directly recognize antigens on the tumor cell surface. However, it cannot recognize target molecules that are confined to the intracellular compartment and are not displayed on the cell surface.
1.3 Functional Evolution of CAR Structures
First-generation CARs mainly contain a CD3ζ signaling domain and show limited cellular expansion and persistence. Second-generation CARs incorporate one costimulatory domain and are currently the most widely used design. Third-generation CARs combine two costimulatory signals, whereas later designs further introduce cytokine-expression modules, safety switches, and multi-antigen logic gates. Increasing CAR structural complexity does not necessarily improve efficacy, and signaling strength must still be balanced against T-cell persistence, functional exhaustion, and treatment-related toxicity.
1.4 Transition From Ex Vivo to In Vivo Engineering
Ex vivo CAR-T manufacturing involves T-cell isolation, activation, gene transfer, and expansion outside the body, followed by infusion of the engineered cells into the patient. In vivo CAR-T uses viral or nonviral vectors to directly deliver CAR-encoding sequences to T cells within the patient. The two pathways may use similar CAR structures, but differ fundamentally in the location of cell engineering, the physical form of the therapeutic product, and the extent of quality control that can be performed before administration.
2 Ex Vivo CAR-T Cell Engineering Process and Quality Control
Figure 1 Cell Collection, Ex Vivo Engineering, and Reinfusion Workflow for CAR-T Therapy
2.1 Collection and Enrichment of Starting Cells
Ex vivo CAR-T cells are generally generated by isolating T cells from the patient’s peripheral blood mononuclear cells. CD4⁺, CD8⁺, naïve, or memory T-cell subsets may be further enriched. Previous treatments, peripheral blood lymphocyte counts, and T-cell functional status affect the quality of the starting material and subsequently influence gene-transfer efficiency, cell-expansion capacity, and the final cellular composition.
2.2 T-Cell Activation
Anti-CD3 and anti-CD28 antibodies or antibody-coated magnetic beads simultaneously provide TCR and costimulatory signals, causing resting T cells to enter a proliferative state and increasing gene-transfer efficiency. Insufficient activation limits transduction and expansion, whereas prolonged or excessively strong stimulation may promote terminal differentiation, activation-induced cell death, and functional exhaustion. The intensity and duration of stimulation therefore require careful control.
2.3 CAR Gene Transfer
Lentiviral and retroviral vectors can stably integrate CAR sequences into the T-cell genome and are suitable for sustained expression. Transposon systems can also achieve stable integration under nonviral conditions, whereas mRNA electroporation produces transient CAR expression and is suitable for high-risk targets or reversible functional validation. These approaches differ in expression duration, cargo capacity, operational complexity, and genetic safety.
2.4 Ex Vivo Expansion and Phenotypic Regulation
After genetic modification, T cells must be expanded under cytokine support to the quantity required for treatment. IL-2 promotes rapid proliferation, but sustained high-intensity IL-2 signaling may drive effector differentiation. IL-7 and IL-15 help maintain certain naïve-like or memory-like phenotypes, whereas IL-21 regulates T-cell differentiation and effector function. Culture duration, cell density, nutrient environment, stimulation duration, and the CD4⁺/CD8⁺ ratio all affect in vivo expansion and persistence of CAR-T cells.
2.5 Harvesting, Formulation, and Storage
After expansion, CAR-T cells must be washed, concentrated, formulated, and cryopreserved when necessary. Cryopreservation and thawing may reduce cell viability and temporarily affect cellular metabolism and cytotoxic function. Viability, CAR expression, cellular composition, and potency should therefore be compared before and after cryopreservation to confirm that storage does not cause unacceptable functional loss.
2.6 Release Testing and Quality Evaluation
Before infusion, CAR-T products generally undergo testing for identity, purity, viability, CAR-positive rate, cell dose, in vitro potency, sterility, mycoplasma, and endotoxin. When integrating vectors are used, vector copy number, replication-competent virus, and long-term genetic safety must also be considered. The CAR-positive rate reflects receptor expression but cannot replace functional evaluation of cytotoxicity, proliferation, and cytokine release.
2.7 Conditioning, Infusion, and In Vivo Monitoring
Patients generally receive lymphodepleting conditioning before CAR-T infusion to reduce competition from endogenous lymphocytes and increase the availability of supportive cytokines. After infusion, CAR-T cell expansion, persistence, tumor burden, blood cell changes, and inflammatory cytokines should be monitored dynamically, with prompt identification of cytokine release syndrome and neurotoxicity.
3 Therapeutic Advantages and Limitations of Ex Vivo CAR-T
3.1 Testing and Selection of Infused Cells
The ex vivo pathway allows direct testing of cell number, CAR expression, subset composition, and in vitro potency before infusion, and batches that do not meet quality requirements can be excluded. Researchers can also adjust the ratio of CD4⁺ to CD8⁺ cells, culture conditions, and input dose, allowing relatively comprehensive process control over the infused cells.
3.2 Capacity for Complex Cellular Engineering
Ex vivo culture provides operational flexibility for multigene editing, receptor modification, and functional screening. In addition to introducing CARs, endogenous TCRs or immune checkpoints may be knocked out, and chemokine receptors, cytokine modules, or safety switches may be introduced. The effects of these modifications can be evaluated before infusion.
3.3 Manufacturing Time and Logistical Complexity
Ex vivo CAR-T involves multiple steps, including cell collection, transport, activation, transduction, expansion, testing, cryopreservation, and reinfusion, and imposes substantial requirements on GMP facilities, trained personnel, quality systems, and cold-chain logistics. Rapid disease progression, insufficient starting cells, or manufacturing failure may prolong treatment waiting time and may even cause patients to miss an appropriate therapeutic window.
3.4 Starting-Cell and Batch Variability
Patient age, previous treatment, disease burden, and immune status cause differences in T-cell number and function. The same manufacturing process may produce different expansion efficiencies, CAR-positive rates, differentiation phenotypes, and cytotoxic activities among patients, making it difficult to completely eliminate batch-to-batch variability in autologous CAR-T products.
3.5 Treatment-Related Toxicity
Rapid CAR-T cell expansion and extensive immune-cell activation can cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). When the target antigen is also expressed in normal tissues, on-target/off-tumor injury may occur.
3.6 Antigen Escape and Functional Exhaustion
Tumors can evade CAR-T recognition by reducing target-antigen expression, selecting antigen-negative cells, or undergoing lineage switching. Persistent antigen stimulation can also induce increased inhibitory receptor expression, metabolic dysfunction, and fixation of epigenetic states, causing CAR-T cells to gradually lose proliferative and cytotoxic capacity.
3.7 Barriers in Solid Tumor Treatment
Abnormal vasculature, dense extracellular matrix, and mismatched chemokine signals in solid tumors restrict CAR-T cell infiltration. Hypoxia, nutrient competition, TGF-β, immunosuppressive cells, and antigen heterogeneity further weaken CAR-T function. Solid tumor CAR-T therapy must therefore address target selection, tissue trafficking, local immunosuppression, and toxicity to normal tissues simultaneously.
4 Mechanism of In Situ Engineering for In Vivo CAR-T
4.1 Direct Generation of CAR-T Cells In Vivo
In vivo CAR-T uses intravenous or local administration to deliver a CAR-encoding system directly into the patient. The vector must sequentially achieve circulatory stability, tissue distribution, T-cell recognition, cellular uptake, and intracellular release, enabling endogenous T cells to express CARs and acquire target-cell recognition and cytotoxic capacity.
Figure 2 Targeted Delivery, In Situ CAR-T Engineering, and Tumor Cell Killing in In Vivo CAR-T Therapy
4.2 Forms of CAR-Encoding Cargo
In vivo delivery may use integrating DNA, nonintegrating DNA, or mRNA. Integrating sequences can produce relatively persistent CAR expression but require control of off-target cell transduction and insertion-related risks. mRNA can be directly translated in the cytoplasm without entering the genome, and its relatively limited expression duration makes it easier to regulate treatment intensity through dose and dosing frequency.
4.3 Targeted Recognition of T Cells
Delivery vectors may recognize T-cell surface molecules such as CD3, CD4, or CD8 through antibodies, antibody fragments, ligands, or engineered viral envelopes. The targeting molecule determines which cellular subset is entered by the vector and may also alter T-cell activation, tissue distribution, and vector internalization. Vector binding to T cells does not necessarily indicate successful CAR expression.
4.4 Cellular Uptake and Intracellular Release
After binding to T cells, vectors generally enter cells through endocytosis. The nucleic acid cargo must escape from endosomes and reach the cytoplasm or nucleus according to the nucleic acid type. mRNA mainly requires endosomal escape and cytoplasmic release, whereas DNA must additionally enter the nucleus. Insufficient efficiency at any step limits the proportion of CAR-positive cells.
4.5 In Vivo Expansion and Establishment of Pharmacological Activity
The effective dose of in vivo CAR-T cannot be represented solely by the administered quantity of the delivery formulation. It also depends on the T-cell transduction rate, CAR expression per cell, differentiation state of transduced cells, and their in vivo expansion. The patient’s immune status, vector clearance rate, and tumor-antigen burden all influence CAR-T cell generation and pharmacodynamic kinetics.
5 Viral and Nonviral Delivery Systems for In Vivo CAR-T
5.1 Engineered Lentiviral and Retroviral Vectors
Lentiviral and retroviral vectors have relatively high gene-transfer capacity. Replacing the viral envelope or linking T-cell-targeting ligands can reduce natural cell tropism and enhance recognition of particular T-cell subsets. Their main advantage is relatively persistent CAR expression, whereas their principal limitations include genomic integration, off-target cell transduction, and difficulty controlling the in vivo dose.
5.2 Adeno-Associated Viral Vectors
Adeno-associated viral vectors can be engineered at the capsid level to modify cellular tropism, but packaging capacity, pre-existing immunity, T-cell transduction efficiency, and accumulation in non-target organs limit their application. Repeat administration may also be restricted by neutralizing antibodies and cellular immune responses. Capsid specificity, tissue distribution, and immunogenicity must therefore be evaluated together.
5.3 Other Engineered Viral Vectors
Adenoviruses, virus-like particles, and other engineered vectors may also be used to deliver CAR sequences or gene-editing components. These platforms provide different options in cargo capacity, expression duration, and cell-entry mechanisms, but all require evaluation of replication risk, immunogenicity, tissue distribution, and manufacturing consistency at scale.
5.4 Lipid Nanoparticles
Lipid nanoparticles (LNPs) can encapsulate CAR mRNA or other nucleic acids and use surface ligands to enhance T-cell targeting. After mRNA is released into the cytoplasm, CAR can be directly expressed without genomic integration, and expression is reversible. The major technical bottlenecks include stability in blood, T-cell uptake, endosomal escape, and distribution to non-target organs such as the liver.
5.5 Polymer and Protein Nanocarriers
Polymer nanoparticles and protein nanoparticles can regulate nucleic acid loading and release through material composition, particle size, charge, and ligand modification. Their designs are flexible, but material toxicity, degradation products, blood compatibility, batch consistency, and large-scale manufacturing require systematic evaluation.
5.6 Extracellular Vesicle Delivery
Extracellular vesicles possess natural lipid membrane structures and can carry mRNA, proteins, or other functional molecules. T-cell recognition can be enhanced through membrane protein engineering. Their principal limitations are cargo-loading efficiency, vesicle heterogeneity, purification standards, and large-scale production.
Table 1 Comparison of Major In Vivo CAR-T Delivery Systems
Delivery System | Main Cargo | CAR Expression Characteristics | Main Advantages | Main Limitations |
Engineered lentiviral or retroviral vectors | Integrating DNA | Relatively persistent | High transduction efficiency and potential for long-term expression | Off-target transduction, genomic integration, and dose control |
Adeno-associated viral vectors | Primarily nonintegrating DNA | Potential for medium- to long-term expression | Relatively mature capsid-engineering system | Packaging capacity, pre-existing immunity, and T-cell transduction efficiency |
Other viral vectors or virus-like particles | DNA, RNA, or editing components | Depends on vector and cargo | Adjustable cargo and cell-entry mechanisms | Immunogenicity, tissue distribution, and manufacturing complexity |
Lipid nanoparticles | mRNA or DNA | mRNA expression is generally transient | Flexible manufacturing and no genomic integration | T-cell targeting, endosomal escape, and organ distribution |
Polymer or protein nanoparticles | mRNA, DNA, or editing components | Depends on cargo | Adjustable materials and release properties | Biocompatibility and in vivo delivery efficiency |
Extracellular vesicles | mRNA or proteins | Generally transient | Natural membrane structure and biocompatibility | Loading efficiency, heterogeneity, and scalable purification |
6 Comparison of Technical Characteristics Between Ex Vivo and In Vivo CAR-T
The core difference between ex vivo and in vivo CAR-T is not the CAR molecule itself but the location where engineering occurs and the object subjected to quality control. The ex vivo pathway directly produces and tests the cells to be infused, whereas the in vivo pathway first controls the delivery formulation and subsequently relies on transduction, expression, and cell expansion within the patient to generate therapeutic CAR-T cells.
Table 2 Comparison of Technical Characteristics Between Ex Vivo and In Vivo CAR-T
Comparison Dimension | Ex Vivo CAR-T | In Vivo CAR-T |
Engineering location | Ex vivo cell-manufacturing system | Within the patient |
Basic process | Collection, activation, transduction, expansion, testing, and infusion | Vector administration, targeted transduction, CAR expression, and in vivo expansion |
Main therapeutic product form | Living-cell product | Viral or nonviral delivery formulation |
CAR expression testing | Can be directly tested before infusion | Evaluated through pharmacodynamic monitoring after administration |
Cell dose | Can be counted and proportioned before infusion | Jointly determined by transduction rate and in vivo expansion |
Cellular subset composition | Can be sorted, adjusted, and tested | Depends on vector targeting and the patient’s T-cell composition |
Complex genetic engineering | Facilitates multigene editing and cell selection | Limited by cargo capacity and in vivo delivery efficiency |
Main quality-control focus | Identity, purity, viability, potency, and microbiological safety | Vector potency, targeting specificity, tissue distribution, and in vivo expression |
Sources of variability | Starting-cell quality and ex vivo culture process | Patient immune status, vector clearance, and transduction variability |
Manufacturing model | Personalized cell manufacturing | More similar to a standardized pharmaceutical formulation |
Main technical advantage | Infused cells can be tested, selected, and proportioned | Reduced ex vivo manufacturing and potential for rapid administration |
Main risks | Manufacturing failure, cellular heterogeneity, and treatment toxicity | Off-target transduction, delivery toxicity, and unpredictable in vivo expression |
7 Challenges in Delivery Efficiency, Functional Persistence, and Safety of In Vivo CAR-T
7.1 T-Cell Targeting Specificity
Delivery vectors must preferentially enter target T cells while avoiding CAR expression in hematopoietic progenitor cells, antigen-presenting cells, hepatocytes, and other non-target cells. Detecting CAR expression only in peripheral blood T cells is insufficient to demonstrate specificity. Vector distribution and the types of transduced cells in the bone marrow, liver, spleen, and other tissues must also be evaluated.
7.2 In Vivo Delivery Efficiency
In vivo delivery efficiency is jointly determined by circulatory stability, target-cell binding, internalization, endosomal escape, nucleic acid release, and expression. Improving one step does not necessarily increase the final number of CAR-T cells. For example, enhanced cellular uptake without improved endosomal escape may still result in degradation of most nucleic acid cargo within lysosomes.
7.3 Endosomal Escape of Nonviral Vectors
After LNPs and polymer vectors enter T cells, their cargo must be released from the endosome into the cytoplasm. Increasing membrane fusion or membrane disruption can improve release efficiency but may also damage cellular membranes, induce inflammation, or increase toxicity in non-target tissues. Delivery efficiency and material safety must therefore be balanced.
7.4 CAR Expression Level and Duration
CAR expression that is too low may be insufficient to form effective immune synapses, whereas excessively high expression may increase tonic signaling, cellular exhaustion, and treatment toxicity. mRNA delivery produces transient expression and facilitates dose regulation but may require repeat administration. Integrating vectors can achieve long-term expression but increase insertion-related risk and the need for long-term follow-up.
7.5 Selection of T-Cell Subsets
Different T-cell subsets differ in vector uptake, transduction, and expansion capacity. If a vector primarily transduces highly differentiated or already exhausted T cells, a high CAR-positive rate may still fail to provide sustained proliferation and long-term tumor control. Delivery targets should account for both cellular specificity and the functional state of the intended subset.
7.6 Immunogenicity and Vector Clearance
Viral envelopes, nanomaterials, targeting antibodies, and foreign CAR structures may all induce innate or adaptive immune responses. Rapid vector clearance reduces transduction efficiency, neutralizing antibodies may restrict repeat dosing, and strong inflammatory responses can increase systemic toxicity.
CAR expression in non-target cells may cause abnormal antigen recognition, tissue injury, or long-term irreversible changes. The risk of integrating-vector transduction of hematopoietic progenitor cells requires particularly strict control because these cells may persist and continuously generate CAR-positive progeny.
7.8 CRS, ICANS, and On-Target Toxicity
In vivo engineering reduces ex vivo manufacturing steps but does not automatically eliminate CRS, ICANS, or on-target/off-tumor effects. Because CAR-T cells may be continuously generated in vivo, their expansion and toxicity kinetics may be more complex than those following a single cellular infusion. Relationships among vector dose, CAR-positive cell number, and inflammatory cytokines must be established.
7.9 Reversible Control and Safety Switches
Transient mRNA, drug-regulated CARs, suicide genes, and degradable receptors may improve the controllability of in vivo CAR-T. Safety mechanisms must be activated rapidly when severe toxicity occurs while avoiding premature termination of therapeutically effective CAR-T cell expansion and persistent responses.
7.10 In Vivo Quality Monitoring
Because in vivo CAR-T cells cannot be fully tested before they are generated in the patient, the delivery formulation must be controlled before administration for particle size, nucleic acid integrity, encapsulation efficiency, potency, targeting activity, and microbiological safety. After administration, the proportion of CAR-positive cells, cellular subsets, vector copy number, cytokines, and tissue distribution must be monitored continuously.
8 Clinical Translation and Future Development of CAR-T Engineering Technologies
8.1 Standardized Manufacturing of Delivery Formulations
In vivo CAR-T may transform part of personalized cellular manufacturing into batch-produced gene-delivery formulations, but clear standards must be established for vector raw materials, particle size, cargo amount, targeting-ligand density, and functional potency. Consistency in physical characterization does not necessarily indicate equivalent in vivo transduction potency, and functional assays capable of predicting T-cell engineering efficiency are still required.
8.2 Dose Selection and Pharmacodynamic Monitoring
The dose of in vivo CAR-T should account for vector particle number, nucleic acid cargo, the proportion of target T cells transduced, and in vivo expansion of CAR-T cells. Clinical monitoring should correlate peripheral blood CAR-positive cell numbers, vector levels, cytokines, and tumor burden rather than defining the effective dose solely according to the administered mass of the delivery formulation.
8.3 Stratified Use of Transient and Persistent Expression
Transient mRNA expression is suitable for targets with narrow safety windows, initial dose exploration, or situations requiring rapid withdrawal of CAR activity. Stable integration is more suitable for diseases requiring long-term immune surveillance. Expression duration should be selected according to disease burden, target-antigen distribution, and reversibility of toxicity.
8.4 Logic Gating and Multi-Antigen Recognition
Multi-antigen recognition and switchable CAR systems can broaden antigen coverage and reduce immune escape caused by loss of a single target antigen. Inhibitory CARs are primarily designed to deliver inhibitory signals upon recognition of antigens associated with normal tissues, thereby improving tumor-recognition selectivity; reducing antigen escape is not their principal function. Complex receptor designs require control of the expression ratios and activation thresholds of individual signaling modules to avoid exhaustion caused by excessive signaling or reduced cytotoxicity caused by overly strict logical conditions.
8.5 Gene Editing and Multi-Cargo Delivery
Delivery systems can simultaneously carry CAR sequences, chemokine receptors, immunosuppression-resistance modules, or gene-editing components to improve tissue trafficking and functional persistence. Multi-cargo designs increase the complexity of cargo capacity, expression ratios, and off-target evaluation. Each functional module should first be shown to provide a clear therapeutic benefit.
8.6 Local Delivery for Solid Tumors
Local or regional delivery can increase vector exposure within tumor tissue and reduce systemic off-target transduction. This strategy is applicable to certain solid tumors that can be directly accessed, but challenges remain in vector distribution throughout the tumor, local inflammation, and migration of engineered T cells to other lesions.
8.7 Parallel Development of Ex Vivo and In Vivo Pathways
The ex vivo pathway is suitable for treatments requiring precise cellular composition, complex multigene editing, and strict pre-infusion testing. The in vivo pathway is more suitable for reducing personalized manufacturing, rapid administration, and repeatable dose adjustment. These approaches may develop in parallel with universal CAR-T cells, point-of-care automated manufacturing, and transient in vivo programming to form a stratified technological system.
8.8 Key Considerations for Clinical Translation
Clinical translation of in vivo CAR-T requires more than demonstrating the generation of CAR-positive T cells in vivo. It must also establish that the transduced cell type is clearly defined, tissue distribution is controllable, CAR-expression kinetics are predictable, severe toxicity can be terminated, and long-term monitoring plans are available for off-target transduction and genetic safety.
9 Products for CAR-T Cell Engineering, Functional Evaluation, and Delivery Research
Catalog # | Product Name | Grade & Purity | Main Application |
Human CD3/CD28 T Cell Activation Magnetic Beads | BioReagent, 1 × 10⁸ beads/mL | Human T-cell activation and ex vivo expansion | |
Mouse CD3/CD28 T Cell Activation Magnetic Beads | 1 × 10⁸ beads/mL | Activation of mouse CAR-T cells and T cells for animal models | |
Recombinant Human IL-2 GMP Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, high-performance, ≥97% (SDS-PAGE & SEC-HPLC) | CAR-T cell expansion and maintenance of effector function | |
Recombinant Human IL-2 Protein | Carrier-free, bioactive, ActiBioPure™, azide-free, high-performance, His Tag, ≥95% (SDS-PAGE) | Research-grade T-cell culture and optimization of expansion conditions | |
Recombinant Human IL-7 GMP Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, high-performance, ≥97% (SDS-PAGE & SEC-HPLC) | Supports survival of naïve-like and memory-like T cells | |
Recombinant Human IL-7 Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, high-performance, sterile, PBS Only, ≥98% (SDS-PAGE & HPLC) | CAR-T culture and maintenance of memory phenotypes | |
Recombinant Human IL-15 GMP Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, high-performance, ≥97% (SDS-PAGE & SEC-HPLC) | Promotes expansion and persistence of memory-like CD8⁺ T cells | |
Recombinant Human IL-15 Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, azide-free, high-performance, PBS Only, ≥97% (SDS-PAGE) | CAR-T expansion and functional persistence studies | |
Recombinant Human IL-21 GMP Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, high-performance, ≥95% (SDS-PAGE & SEC-HPLC) | Regulation of T-cell expansion, differentiation, and effector phenotype | |
Recombinant Human IL-21 Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, azide-free, high-performance, PBS Only, ≥97% (SDS-PAGE & HPLC) | Optimization of CAR-T culture conditions | |
Hexadimethrine bromide | ≥90% | Assists lentiviral or retroviral transduction | |
Protamine sulfates | — | Promotes the binding of certain viral vectors to the cell surface | |
Viral Transfection Enhancer | BioReagent, ready-to-use, for cell culture, Suitable for molecular biology, sterile | Optimization of viral-vector transduction conditions | |
Serum/Protein-Free Cell Freezing Medium | Sterile-filtered, BioReagent, endotoxin-tested, ready-to-use, for cell culture, sterile | Cryopreservation and recovery of CAR-T and other immune cells | |
Rapid Cell Freezing Medium (Serum-Free) | Sterile-filtered, BioReagent, endotoxin-tested, ready-to-use, for cell culture | Rapid cryopreservation of CAR-T cells | |
Rapid Cell Freezing Medium (Serum-Free) | Sterile-filtered, BioReagent, endotoxin-tested, ready-to-use, for cell culture | CAR-T cell preservation | |
UltraBio™ tissue/cell storage solution | — | Screening of cell cryopreservation conditions | |
Cell Freezing Medium（Serum-free, DMSO-free） | BioReagent, endotoxin-tested, for cell culture, sterile | DMSO-free cryopreservation and post-thaw functional studies |
9.2 Products for Detecting CAR Signaling, T-Cell Identity, and Activation Status
Catalog # | Product Name | Grade & Purity | Main Application |
CD3 zeta Antibody | Carrier-free, ExactAb™, validated, high-performance, 0.5 mg/mL | CD3ζ expression and CAR signaling-domain studies | |
Recombinant CD3 Antibody | Animal Free, carrier-free, recombinant, ExactAb™, azide-free, validated, high-performance, PBS Only, ≥95% (SDS-PAGE), see COA | T-cell identity and CD3 expression detection | |
Recombinant CD3 Antibody (APC) | Recombinant, ExactAb™, validated, site-specific conjugation, 5 μL/test | Flow-cytometric detection of the proportion of CD3⁺ T cells | |
Recombinant CD3 Antibody (FITC) | Recombinant, ExactAb™, validated, 5 μL/test | Multicolor flow-cytometric T-cell phenotyping | |
Recombinant CD3 Antibody (PE) | Recombinant, ExactAb™, validated, 5 μL/test | Multicolor flow-cytometric identification of T cells | |
Recombinant CD3 Antibody (APC-Cy7) | Recombinant, ExactAb™, validated, site-specific conjugation, 5 μL/test | Identification of T cells in high-parameter flow cytometry | |
Recombinant CD28 Antibody | Carrier-free, recombinant, ExactAb™, low endotoxin, azide-free, validated, PBS Only, ≥99% (SEC-HPLC), see COA | CD28 expression, binding, and costimulatory pathway studies | |
CD28 Mouse mAb (APC) | ExactAb™, validated, 5 μL/test | Flow-cytometric detection of the CD28 costimulatory receptor | |
CD28 Mouse mAb (FITC) | ExactAb™, validated, 5 μL/test | CD28 phenotypic analysis of CAR-T cells | |
CD28 Mouse mAb (PE) | ExactAb™, validated, 5 μL/test | Multicolor flow-cytometric detection of CD28 expression | |
Recombinant IL-2 Receptor alpha/CD25 Antibody | Animal Free, carrier-free, recombinant, ExactAb™, azide-free, validated, high-performance, PBS Only, ≥95% (SDS-PAGE), see COA | Detection of the T-cell activation marker CD25 | |
Recombinant IL-2 Receptor alpha/CD25 Antibody (FITC) | Recombinant, ExactAb™, validated, 5 μL/test | Flow-cytometric detection of CAR-T activation status | |
Recombinant IL-2 Receptor alpha/CD25 Antibody (PE) | Recombinant, ExactAb™, validated, 5 μL/test | Multicolor flow-cytometric analysis of CD25 expression | |
Recombinant IL-2 Receptor alpha/CD25 Antibody (APC) | Recombinant, ExactAb™, validated, 5 μL/test | High-parameter flow-cytometric detection of T-cell activation | |
Recombinant Human CD28 Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, His Tag, Fc tag, PBS Only, ≥95% (SDS-PAGE), see COA | CD28 antibody binding, ligand interactions, and costimulatory mechanism studies | |
Recombinant Human CD28 Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, His Tag, PBS Only, ≥95% (SDS-PAGE), see COA | CD28-related protein-interaction studies |
9.3 Products for CAR-T Costimulatory Pathway and Gene-Function Research
Catalog # | Product Name | Grade & Purity | Main Application |
CD28 Human Pre-designed siRNA Set A | — | Reduces human CD28 expression for studies of costimulatory signaling | |
Cd28 Mouse Pre-designed siRNA Set A | — | Studies of CD28 function in mouse T cells | |
Cd28 Rat Pre-designed siRNA Set A | — | Studies of CD28 signaling in rats | |
pLenti-CD28-sgRNA | — | Validation of CD28 antibody specificity in protein detection | |
pLenti-CD28-sgRNA | — | Validation of CD28 nucleic acid detection specificity | |
Recombinant Human CD25/IL-2R alpha Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, His Tag, PBS Only, ≥95% (SDS-PAGE) | IL-2 receptor binding and T-cell activation mechanism studies | |
Recombinant Human IL-2 R beta Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, high-performance, His Tag, ≥90% (SDS-PAGE) | Studies of IL-2 receptor β-chain signaling | |
Recombinant Human IL-2 Receptor Alpha Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, azide-free, high-performance, His Tag, ≥97% (SDS-PAGE) | IL-2/CD25 binding and receptor-function studies | |
Recombinant Human IL-7R alpha/CD127 Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, His Tag, ≥90% (SDS-PAGE) | Studies of IL-7-mediated T-cell survival and memory phenotypes | |
Recombinant IL-15RA Antibody | Recombinant, ExactAb™, validated, 1.0 mg/mL | IL-15 receptor expression and signaling studies | |
Recombinant Human IL-21R Protein | Animal Free, carrier-free, bioactive, ActiBioPure™, azide-free, high-performance, His Tag, ≥92% (SDS-PAGE) | IL-21 receptor binding and cytokine signaling studies |
9.4 Products for Monitoring In Vivo CAR-T Targeting Specificity and Non-Target Cells
Catalog # | Product Name | Grade & Purity | Main Application |
Recombinant CD16/CD32 Antibody | Animal Free, carrier-free, recombinant, ExactAb™, azide-free, validated, high-performance, PBS Only, ≥95% (SDS-PAGE), see COA | Detection of Fc receptor-positive cells and analysis of non-target cells | |
Recombinant CD16/CD32 Antibody (AF488) | Recombinant, ExactAb™, validated, 0.5 mg/mL | Flow-cytometric analysis of Fc receptor-positive cells | |
CLEC10A/CD301 Antibody | See COA | Detection of CLEC10A-positive dendritic or myeloid cells | |
CLEC9A/CD370 Antibody | See COA | Detection of CLEC9A-positive dendritic cells | |
Recombinant CD31 Antibody (APC) | Recombinant, ExactAb™, validated, 5 μL/test | Monitoring of CD31-positive non-target cells such as endothelial cells | |
Recombinant CD34 Antibody | Animal Free, carrier-free, recombinant, ExactAb™, azide-free, validated, high-performance, PBS Only, ≥95% (SDS-PAGE), see COA | Monitoring of off-target transduction risk in hematopoietic progenitor cells | |
Recombinant CD335/NKp46 Antibody (PE) | ExactAb™, validated, 0.5 mg/mL | Differentiation of NK cells from engineered T cells | |
Recombinant CD32 Antibody | Recombinant, ExactAb™, validated, see COA | Phenotypic detection of CD32-positive cells | |
Recombinant CD32A Antibody | Recombinant, ExactAb™, validated, see COA | Analysis of activating Fc receptor-positive cells | |
Recombinant CD32B Antibody | Recombinant, ExactAb™, validated, 0.8 mg/mL | Analysis of inhibitory Fc receptor-positive cells |
CAR-T engineering is extending from controllable ex vivo cell manufacturing toward precise in vivo delivery. The ex vivo pathway emphasizes that infused cells can be tested, selected, and proportioned, whereas the in vivo pathway emphasizes vector targeting specificity, tissue distribution, expression kinetics, and reversibility of toxicity.
For more related articles, please see below:
[1] Lentiviruses and Lentiviral Vectors: Engineering from Natural Viruses to Gene Delivery Tools
危险品化学品经营许可证（带存储）